BEONE MEDICINES LTD

Beone Medicines (6160.HK) dips 2.94% to HKD 227.80—market cap HKD 47.1B. 200‑day SMA at HKD 194.30, 52‑week high HKD 236, awaiting Q2 2027 Phase III CAR‑T trial.

Beone Medicines jumps 6.3% after a Q3 earnings beat and strong PD‑L1 pipeline, but its 90x PE and single‑product focus raise caution for investors.

Beone Medicines sees solid‑tumour breakthroughs yet faces valuation and liquidity concerns—investors weigh rapid pipeline growth against market‑cap risk and peer performance.